Cognitive Impact of Alzheimer’s and Cardiovascular Genetic Risk Scores in FINGER Trial
Overview
The FINGER randomized controlled trial investigated the influence of Alzheimer’s disease and coronary artery disease genetic risk scores (AD-GRS and CAD-GRS) on cognitive outcomes following a 2-year multidomain lifestyle intervention. Results showed that individuals with higher genetic risk for Alzheimer's or coronary artery disease benefited cognitively from the intervention, with notable gender differences observed for AD-GRS.
Background
Alzheimer's disease and coronary artery disease are prevalent chronic conditions in older adults, sharing genetic and lifestyle risk factors including the APOE ε4 allele. Multidomain lifestyle interventions targeting multiple risk factors have demonstrated cognitive benefits and cardiovascular health improvements. While APOE4 status has been studied in relation to intervention efficacy, the impact of broader polygenic risk scores for Alzheimer's and coronary artery disease on cognitive outcomes remains underexplored. The FINGER trial provides a platform to assess how these genetic risk scores interact with lifestyle interventions to influence cognition.
Data Highlights
Genetic Risk Group
Intervention-Control Difference in Annual Overall Cognition Change (95% CI)
AD-GRS Above Median (Higher Risk)
0.032 (0.002–0.063)
AD-GRS Below Median (Lower Risk)
0.017 (−0.011 to 0.045)
CAD-GRS Above Median (Higher Risk)
0.031 (0.002 to 0.059)
CAD-GRS Below Median (Lower Risk)
0.016 (−0.012 to 0.044)
AD-GRS Higher-Risk Females
0.045 (0.004 to 0.087)
AD-GRS Lower-Risk Females
0.003 (−0.040 to 0.047)
AD-GRS Higher-Risk Males
0.019 (−0.026 to 0.064)
AD-GRS Lower-Risk Males
0.027 (−0.009 to 0.064)
Key Findings
Both higher AD-GRS and CAD-GRS groups showed greater cognitive benefits from the multidomain lifestyle intervention compared to lower-risk groups.
No significant overall interaction was found between genetic risk scores and intervention effect (P > 0.46).
Significant gender differences were observed for AD-GRS, with higher-risk females benefiting more than lower-risk females (P = 0.024).
The cognitive benefit in higher-risk females (AD-GRS) was 0.045 annual score change versus 0.003 in lower-risk females.
APOE4 carrier status findings were consistent with AD-GRS and CAD-GRS results, supporting genetic susceptibility does not negate intervention benefits.
These findings are exploratory and require validation in larger, genetically diverse populations and additional multidomain lifestyle trials.
Clinical Implications
Multidomain lifestyle interventions can provide cognitive benefits even in individuals with high genetic risk for Alzheimer's disease or coronary artery disease, supporting their use in precision prevention strategies. Gender differences in response, particularly among females with higher AD-GRS, highlight the need for tailored approaches. Genetic risk scores may help identify individuals who could gain the most from lifestyle modifications but should be integrated cautiously pending further validation.
Conclusion
The FINGER trial demonstrates that genetic susceptibility to Alzheimer's and coronary artery disease does not preclude cognitive benefits from multidomain lifestyle interventions, with potential gender-specific effects for Alzheimer's genetic risk. These findings underscore the promise of lifestyle-based prevention across genetic risk strata but warrant confirmation in future studies.
References
Ngandu et al. 2015 -- The FINGER Study: Multidomain Intervention for Dementia Prevention
Kivipelto et al. 2020 -- APOE4 and Cognitive Benefits of Lifestyle Interventions
Jansen et al. 2019 -- Polygenic Risk Scores for Alzheimer's Disease
Inouye et al. 2018 -- Genetic Risk Scores for Coronary Artery Disease
by Gazi Saadmaan, Maria Carolina Dalmasso, Maleeha Maria, Jenni Lehtisalo, Mikko Hiltunen, Minna U Kaikkonen, Esko Levälahti, Francesca Mangialasche, Markus Perola, Alfredo Ramirez, Ruth Stephen, Tiia Ngandu, Miia Kivipelto, Alina Solomon
